Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
August 21, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for November 10, 2005 Subscribe to this News Feed     Subscribe to this Podcast Feed  
 

Bio-era Presents Expert Testimony before the Senate Foreign Relations Committee on the Economic Risks of Bird Flu Pandemic

Warns Congress about the effects of fear, and recommends increased investment in global disease surveillance and response.

Cambridge, MA (PRWEB) November 10, 2005 -- James Newcomb, Managing Director of Bio Economic Research Associates (bio-eraTM) presented testimony today before the Senate Foreign Relations Committee regarding the economic consequences and risks associated with the emergence of a highly virulent pandemic influenza virus.

The Avian influenza crisis in Asia has already caused more than $15 billion dollars in damage in the economies of the most-seriously affected countries, but this is just the tip of the iceberg compared with the possible global economic consequences of a human influenza pandemic, which the World Bank and others have estimated at potentially causing up to $850 billion in damage to the world economy.

From a policy perspective, our analysis of these risks underscores the message that
“The bottom line is that a pandemic could affect our highly integrated global economy in a way that has no real precedent in recent decades” Newcomb told the Committee. “The first wave of economic impacts would result from fearful anticipatory reactions to the spread of the disease; these effects include shocks to financial markets, reductions in consumption and investment, and disruptions of trade and travel… Reactive and uncoordinated national actions to close borders or embargo trade could be exactly the wrong prescription in the early days of pandemic emergence. These could inadvertently fuel fears at the point of emergence and compound the challenges of disease management on the ground. Shutting down transportation hubs, such as airports and ports, would disrupt key supply chains and create unpredictable secondary effects that would compound the effects of the initial outbreak. These feedbacks, coupled with growing fears about the disease itself, would be increasingly difficult to manage as the pandemic spreads globally.”

“The second wave of economic impacts would be experienced as a result of the spread of the disease itself, with potentially large impacts on the workforce and the flow of goods and services as well as the overburdened medical system. While these direct economic impacts of the disease could be quite significant, these costs are almost certainly manageable from a macroeconomic perspective, even in the case of a moderate pandemic, provided they are not overly compounded by fear-driven reactions.”

“From a policy perspective, our analysis of these risks underscores the message that “an ounce of prevention is worth a pound of cure.”

The bio-era testimony summarizes and interprets the latest economic analysis relevant to the current outbreak of Avian influenza (H5N1) in Southeast Asia, including the economic burdens imposed so far by the disease, and the risks and potential impacts should the current outbreak develop into a global influenza pandemic.

“We’ve been looking at how things might unfold under six very different but highly plausible scenarios for the evolution of the outbreak,” said Stephen Aldrich, President of bio-era. “In the process, we’ve made assessments of potential outbreak risk by country, the relative economic exposure by country -- and how selected industries and companies are likely to be affected.”

This on-going work is a part of bio-era’s recently launched service “Thinking Ahead: Anticipating Early Impacts of an Avian Influenza Pandemic”, designed to support business and investment planning efforts in advance of a possible influenza pandemic.

To discuss the Senate testimony, please call James Newcomb, at 303 247-1711, or Steve Aldrich at 617 876-2400. The full testimony is available at http://www.bio-era.net.

Bio Economic Research Associates (bio-era™) is a leading provider of independent research and advisory services on the emerging bio economy. Bio - era’s mission is to help decision-makers understand and respond to the risks and opportunities arising from the economic and societal impacts of human-induced changes to biological systems. The firm’s practice areas include biosecurity, bioenergy, and biotechnology.

# # #

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
Stephen Aldrich
BIO-ERA, LLC
617 876-2400
Email us Here
ATTACHED FILES

Bio-era Senate Testimony
This is the testimony given by James Newcomb, Managing Director for Research at bio-era to the Senate Foreign Relations Committe on 11/09/05 on the Economic Risks Associated with Influenza Pandemic

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright